New biologic drug JANX014 enters first human trial for tough prostate cancer

NCT ID NCT07545811

Recruiting now Disease control Sponsor: Janux Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through the body and whether it shows any signs of shrinking tumors. It is a first-in-human study, so results will guide whether further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JANX014 (a biologic drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 43 participants, focused mainly on safety. It may not show enough benefit or could have side effects that limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Prisma Health Cancer Institute
RECRUITING

Greenville, South Carolina, 29605, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
SCRI at Mary Crowley
RECRUITING

Dallas, Texas, 75230, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.